Detailed narrative
Strong Revenue and Gross Margin Performance
Tenon Medical reported record second-quarter revenue of $1.3 million, marking a 127% increase over the prior year. First-half revenue also saw substantial growth, reaching $2.7 million, up 106% from $1.3 million in the first six months of 2025. This top-line growth was accompanied by significant gross margin expansion, with Q2 gross margin at 64% (up from 43% year-over-year) and first-half gross margin at 66% (up from 44% in H1 2025). The improvement is attributed to higher case volumes, improved absorption of fixed production overhead, and streamlined commercial operations.
Commercial Expansion and Training Initiatives
The company is actively expanding its commercial footprint, including hiring a seasoned professional sales lead for the East Coast and planning to add further sales heads and distributor partners in the second half of the year. Physician and distributor training activity saw a meaningful uptick in Q2, with training events increasing 98% in the first half of 2026 compared to the second half of 2025. This surge is largely driven by the newly opened Tampa sales and training office, which has contributed to a record case volume month in July and a strong start to Q3.
Regulatory Clearances and Product Development Pipeline
Subsequent to the quarter end, Tenon Medical received FDA 510k clearance for the Catamaran SI joint fusion system, which includes instrument upgrades and reclassification of certain instruments to reusable status. This is expected to improve system performance and reduce per-procedure costs, positively impacting margins from Q3. The company also has multiple R&D initiatives nearing launch, including an enhanced Symmetry Plus system with streamlined decortication (clinically active in Q3), an enhanced feature for the Symmetry Plus implant nearing 510 approval filing, and a third novel product offering for the sacral pelvic space.
Financial Position and Capital Allocation
The company ended Q2 FY26 with $1.7 million in cash and cash equivalents, down from $3.8 million at the end of 2025. To bolster its financial runway, Tenon Medical closed a public offering on July 1, generating aggregate gross proceeds of $4.2 million. Net proceeds are earmarked for partial repayment of outstanding convertible notes, commercial expansion, clinical research, and general corporate purposes. The increase in net loss for the quarter and first half was primarily due to a $0.9 million non-cash interest expense related to the amortization of the original issue discount on convertible notes.
Strategic Focus for Second Half of Year
Management's focus for the remainder of the year is narrow: growing procedure volumes for both Catamaran and Symmetry Plus platforms, continuing aggressive physician training and education, accelerating key R&D projects, and protecting the gross margin gains achieved. The company believes its current strategy and recent actions position it for continued growth into 2027 while maintaining a disciplined cost base and executing on commercial and product launch initiatives.